SCHEMBL2745152

SCHEMBL2745152

CCOC(=O)C(C)Cc1cccc(OCc2c(C)cccc2C)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.49
MAPK1 P28482 3/20 0.49
TSHR P16473 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
FFAR1 O14842 1/20 0.46
SLC22A12 Q96S37 4/20 0.46
LMNA P02545 1/20 0.44
MME P08473 1/20 0.43
ACE P12821 1/20 0.43
CPA1 P15085 1/20 0.43
ACE2 Q9BYF1 1/20 0.43
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
CYSLTR2 Q9NS75 1/20 0.41
CYSLTR1 Q9Y271 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PTGES O14684 1/20 0.40
MAOB P27338 1/20 0.40
SOD1 P00441 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2744644 0.87 FFAR1 (0.59) FFAR1SLC22A12MMEACECPA1
SCHEMBL2744642 0.87 FFAR1 (0.59) FFAR1SLC22A12MMEACECPA1
SCHEMBL2744646 0.87 FFAR1 (0.59) FFAR1SLC22A12MMEACECPA1
SCHEMBL8563484 0.81 MMP8 (0.46) L3MBTL1MAPK1TSHRTDP1LMNA
SCHEMBL1010327 0.81 SLC22A12 (0.50) L3MBTL1MAPK1TSHRTDP1SLC22A12
SCHEMBL1634517 0.80 PPARA (0.48) FFAR1SLC22A12MMEACECPA1
SCHEMBL1007732 0.80 ALOX5 (0.45) L3MBTL1MAPK1TSHRTDP1FFAR1
SCHEMBL20905349 0.79 MAOB (0.56) TSHRFFAR1MMEACECPA1
SCHEMBL26896022 0.79 MAOB (0.56) TSHRFFAR1MMEACECPA1
SCHEMBL1634208 0.79 PPARA (0.54) L3MBTL1MAPK1TSHRTDP1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948152-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORP (US) 2013-01-02 EP disclosed
US-8178675-B2 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2012-05-15 US disclosed
US-20090203793-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2009-08-13 US disclosed
EP-1948152-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2008-07-30 EP disclosed
WO-2007056771-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203793-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS CPT1B, CPT1A, GOT2 L3MBTL1 1569/4885MAPK1 1707/4885TSHR 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.